Factors associated with prescribing restriction on oncology formulary drugs in Malaysia

Background Drugs listed on formularies are often subjected to a variety of utilization restriction measures. However, the degree of restriction is influenced by multiple factors, including the characteristics and attributes of the listed drugs. Objective To identify the factors that are associated w...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical pharmacy 2016-10, Vol.38 (5), p.1075-1079
Main Authors: Fatokun, Omotayo, Olawepo, Michael N.
Format: Article
Language:English
Subjects:
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Cancer therapies
Decision making
Drug Prescriptions - standards
Drug therapy
Female
Health Personnel - standards
Humans
Internal Medicine
Malaysia - epidemiology
Male
Medicine
Medicine & Public Health
Neoplasms - drug therapy
Neoplasms - epidemiology
Pharmacopoeias as Topic - standards
Pharmacy
Prescription drugs
Short Research Report
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Drugs listed on formularies are often subjected to a variety of utilization restriction measures. However, the degree of restriction is influenced by multiple factors, including the characteristics and attributes of the listed drugs. Objective To identify the factors that are associated with the levels of prescribing restriction on oncology formulary drugs in Malaysia. Setting Oncology formulary in Malaysia. Method The Malaysia Drug Code assigned to each of the drug products on the Malaysia Ministry of Health (MOH) drug formulary was used to identify oncology drugs belonging to WHO ATC class L (antineoplastic and immunomodulating agents). Main outcome measures Categories of prescribing restrictions, therapeutic class, drug type, administration mode, number of sources and the post-approval use period. Results Oncology drugs having a shorter post-approval use period ( p  
ISSN:2210-7703
2210-7711
DOI:10.1007/s11096-016-0372-8